Compare · NVO vs RANI
NVO vs RANI
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rani Therapeutics Holdings Inc. (RANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RANI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.18B, about 2462.9x RANI ($74.8M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for RANI).
- NVO has more recent analyst coverage (25 ratings vs 14 for RANI).
- Company
- Novo Nordisk A/S
- Rani Therapeutics Holdings Inc.
- Price
- -
- -
- Market cap
- $184.18B
- $74.8M
- 1M return
- +6.11%
- -
- 1Y return
- -14.12%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 14
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RANI
- Rani Therapeutics Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Amendment: SEC Form SCHEDULE 13G/A filed by Rani Therapeutics Holdings Inc.
- SEC Form 10-Q filed by Rani Therapeutics Holdings Inc.
- Rani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
- Rani Therapeutics to Participate in the Chardan Healthcare Conference
- Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
- Chief Executive Officer Imran Talat covered exercise/tax liability with 7,928 shares, decreasing direct ownership by 2% to 461,808 units (SEC Form 4) to satisfy withholding obligation
- Chief Technical Officer Javadi Alireza covered exercise/tax liability with 309 shares, decreasing direct ownership by 3% to 9,071 units (SEC Form 4) (for tax liability)
- Rani Therapeutics to Participate in Upcoming September Conferences